Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels
High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advan...
Gespeichert in:
| Veröffentlicht in: | Pancreas 2015-07, Vol.44 (5), p.756-763 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 763 |
|---|---|
| container_issue | 5 |
| container_start_page | 756 |
| container_title | Pancreas |
| container_volume | 44 |
| creator | Miura, Tomofumi Mitsunaga, Shuichi Ikeda, Masafumi Shimizu, Satoshi Ohno, Izumi Takahashi, Hideaki Furuse, Junji Inagaki, Masatoshi Higashi, Sayumi Kato, Hiroyuki Terao, Kimio Ochiai, Atsushi |
| description | High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy.
Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels.
Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels.
High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC. |
| doi_str_mv | 10.1097/MPA.0000000000000335 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687995091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1687995091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-60d0aa45972bedfaa6038479dad4ffd4a705956aca6bdf18755e28a59d675b213</originalsourceid><addsrcrecordid>eNpdkMtOwzAQRS0EoqXwBwh5ySbFjuPXsqp4SUWwgHWY2A4JpE6xkyL4elK1IMRsZnTnzh3pIHRKyZQSLS_uHmZT8rcY43toTDkTSaZStY_GRCmeMCrlCB3F-EoIlYzrQzRKuWY05XyMnucVBDCdC_UXdHXrcVvi1TA530X8UXcVBrsGb5wdZG-CG3YGm40SMHiLq_qlwtGFfolrP-Q0rn-rfSJw49auicfooIQmupNdn6Cnq8vH-U2yuL--nc8WiWFcdYkglgBkXMu0cLYEEISpTGoLNitLm4EkXHMBBkRhS6ok5y5VwLUVkhcpZRN0vs1dhfa9d7HLl3U0rmnAu7aPORVKas2J3lizrdWENsbgynwV6iWEz5ySfMM2H9jm_9kOZ2e7D32xdPb36Acm-waLpXW6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687995091</pqid></control><display><type>article</type><title>Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Miura, Tomofumi ; Mitsunaga, Shuichi ; Ikeda, Masafumi ; Shimizu, Satoshi ; Ohno, Izumi ; Takahashi, Hideaki ; Furuse, Junji ; Inagaki, Masatoshi ; Higashi, Sayumi ; Kato, Hiroyuki ; Terao, Kimio ; Ochiai, Atsushi</creator><creatorcontrib>Miura, Tomofumi ; Mitsunaga, Shuichi ; Ikeda, Masafumi ; Shimizu, Satoshi ; Ohno, Izumi ; Takahashi, Hideaki ; Furuse, Junji ; Inagaki, Masatoshi ; Higashi, Sayumi ; Kato, Hiroyuki ; Terao, Kimio ; Ochiai, Atsushi</creatorcontrib><description>High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy.
Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels.
Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels.
High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.</description><identifier>ISSN: 0885-3177</identifier><identifier>EISSN: 1536-4828</identifier><identifier>DOI: 10.1097/MPA.0000000000000335</identifier><identifier>PMID: 25931255</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; Anemia - blood ; Anemia - etiology ; Biomarkers, Tumor - blood ; Body Composition ; C-Reactive Protein - analysis ; Cachexia - blood ; Cachexia - etiology ; Carcinoembryonic Antigen - analysis ; Chi-Square Distribution ; Fatigue - blood ; Fatigue - etiology ; Female ; Humans ; Interleukin-6 - blood ; Liver Neoplasms - blood ; Liver Neoplasms - secondary ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - complications ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Prognosis ; Prospective Studies ; Risk Factors ; Tumor Burden ; Up-Regulation</subject><ispartof>Pancreas, 2015-07, Vol.44 (5), p.756-763</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-60d0aa45972bedfaa6038479dad4ffd4a705956aca6bdf18755e28a59d675b213</citedby><cites>FETCH-LOGICAL-c358t-60d0aa45972bedfaa6038479dad4ffd4a705956aca6bdf18755e28a59d675b213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25931255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miura, Tomofumi</creatorcontrib><creatorcontrib>Mitsunaga, Shuichi</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Shimizu, Satoshi</creatorcontrib><creatorcontrib>Ohno, Izumi</creatorcontrib><creatorcontrib>Takahashi, Hideaki</creatorcontrib><creatorcontrib>Furuse, Junji</creatorcontrib><creatorcontrib>Inagaki, Masatoshi</creatorcontrib><creatorcontrib>Higashi, Sayumi</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Terao, Kimio</creatorcontrib><creatorcontrib>Ochiai, Atsushi</creatorcontrib><title>Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels</title><title>Pancreas</title><addtitle>Pancreas</addtitle><description>High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy.
Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels.
Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels.
High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia - blood</subject><subject>Anemia - etiology</subject><subject>Biomarkers, Tumor - blood</subject><subject>Body Composition</subject><subject>C-Reactive Protein - analysis</subject><subject>Cachexia - blood</subject><subject>Cachexia - etiology</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>Chi-Square Distribution</subject><subject>Fatigue - blood</subject><subject>Fatigue - etiology</subject><subject>Female</subject><subject>Humans</subject><subject>Interleukin-6 - blood</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - secondary</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - complications</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Tumor Burden</subject><subject>Up-Regulation</subject><issn>0885-3177</issn><issn>1536-4828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMtOwzAQRS0EoqXwBwh5ySbFjuPXsqp4SUWwgHWY2A4JpE6xkyL4elK1IMRsZnTnzh3pIHRKyZQSLS_uHmZT8rcY43toTDkTSaZStY_GRCmeMCrlCB3F-EoIlYzrQzRKuWY05XyMnucVBDCdC_UXdHXrcVvi1TA530X8UXcVBrsGb5wdZG-CG3YGm40SMHiLq_qlwtGFfolrP-Q0rn-rfSJw49auicfooIQmupNdn6Cnq8vH-U2yuL--nc8WiWFcdYkglgBkXMu0cLYEEISpTGoLNitLm4EkXHMBBkRhS6ok5y5VwLUVkhcpZRN0vs1dhfa9d7HLl3U0rmnAu7aPORVKas2J3lizrdWENsbgynwV6iWEz5ySfMM2H9jm_9kOZ2e7D32xdPb36Acm-waLpXW6</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Miura, Tomofumi</creator><creator>Mitsunaga, Shuichi</creator><creator>Ikeda, Masafumi</creator><creator>Shimizu, Satoshi</creator><creator>Ohno, Izumi</creator><creator>Takahashi, Hideaki</creator><creator>Furuse, Junji</creator><creator>Inagaki, Masatoshi</creator><creator>Higashi, Sayumi</creator><creator>Kato, Hiroyuki</creator><creator>Terao, Kimio</creator><creator>Ochiai, Atsushi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels</title><author>Miura, Tomofumi ; Mitsunaga, Shuichi ; Ikeda, Masafumi ; Shimizu, Satoshi ; Ohno, Izumi ; Takahashi, Hideaki ; Furuse, Junji ; Inagaki, Masatoshi ; Higashi, Sayumi ; Kato, Hiroyuki ; Terao, Kimio ; Ochiai, Atsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-60d0aa45972bedfaa6038479dad4ffd4a705956aca6bdf18755e28a59d675b213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia - blood</topic><topic>Anemia - etiology</topic><topic>Biomarkers, Tumor - blood</topic><topic>Body Composition</topic><topic>C-Reactive Protein - analysis</topic><topic>Cachexia - blood</topic><topic>Cachexia - etiology</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>Chi-Square Distribution</topic><topic>Fatigue - blood</topic><topic>Fatigue - etiology</topic><topic>Female</topic><topic>Humans</topic><topic>Interleukin-6 - blood</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - secondary</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - complications</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Tumor Burden</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miura, Tomofumi</creatorcontrib><creatorcontrib>Mitsunaga, Shuichi</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Shimizu, Satoshi</creatorcontrib><creatorcontrib>Ohno, Izumi</creatorcontrib><creatorcontrib>Takahashi, Hideaki</creatorcontrib><creatorcontrib>Furuse, Junji</creatorcontrib><creatorcontrib>Inagaki, Masatoshi</creatorcontrib><creatorcontrib>Higashi, Sayumi</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Terao, Kimio</creatorcontrib><creatorcontrib>Ochiai, Atsushi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pancreas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miura, Tomofumi</au><au>Mitsunaga, Shuichi</au><au>Ikeda, Masafumi</au><au>Shimizu, Satoshi</au><au>Ohno, Izumi</au><au>Takahashi, Hideaki</au><au>Furuse, Junji</au><au>Inagaki, Masatoshi</au><au>Higashi, Sayumi</au><au>Kato, Hiroyuki</au><au>Terao, Kimio</au><au>Ochiai, Atsushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels</atitle><jtitle>Pancreas</jtitle><addtitle>Pancreas</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>44</volume><issue>5</issue><spage>756</spage><epage>763</epage><pages>756-763</pages><issn>0885-3177</issn><eissn>1536-4828</eissn><abstract>High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy.
Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels.
Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels.
High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.</abstract><cop>United States</cop><pmid>25931255</pmid><doi>10.1097/MPA.0000000000000335</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3177 |
| ispartof | Pancreas, 2015-07, Vol.44 (5), p.756-763 |
| issn | 0885-3177 1536-4828 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687995091 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Age Factors Aged Aged, 80 and over Anemia - blood Anemia - etiology Biomarkers, Tumor - blood Body Composition C-Reactive Protein - analysis Cachexia - blood Cachexia - etiology Carcinoembryonic Antigen - analysis Chi-Square Distribution Fatigue - blood Fatigue - etiology Female Humans Interleukin-6 - blood Liver Neoplasms - blood Liver Neoplasms - secondary Logistic Models Male Middle Aged Multivariate Analysis Pancreatic Neoplasms - blood Pancreatic Neoplasms - complications Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Prognosis Prospective Studies Risk Factors Tumor Burden Up-Regulation |
| title | Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A59%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20patients%20with%20advanced%20pancreatic%20cancer%20and%20high%20serum%20interleukin-6%20levels&rft.jtitle=Pancreas&rft.au=Miura,%20Tomofumi&rft.date=2015-07-01&rft.volume=44&rft.issue=5&rft.spage=756&rft.epage=763&rft.pages=756-763&rft.issn=0885-3177&rft.eissn=1536-4828&rft_id=info:doi/10.1097/MPA.0000000000000335&rft_dat=%3Cproquest_cross%3E1687995091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687995091&rft_id=info:pmid/25931255&rfr_iscdi=true |